155 related articles for article (PubMed ID: 36305832)
21. Unfinished business: Terminated cancer trials and the relevance of treatment intent, sponsors and intervention types.
Buergy D; Riedel J; Sarria GR; Ehmann M; Scafa D; Grilli M; Wenz F; Hofheinz RD
Int J Cancer; 2021 Apr; 148(7):1676-1684. PubMed ID: 33045097
[TBL] [Abstract][Full Text] [Related]
22. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
23. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement.
Tang C; Sherman SI; Price M; Weng J; Davis SE; Hong DS; Yao JC; Buzdar A; Wilding G; Lee JJ
Clin Cancer Res; 2017 Mar; 23(6):1414-1421. PubMed ID: 28275168
[No Abstract] [Full Text] [Related]
24. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.
Khan MS; Shahid I; Asad N; Greene SJ; Khan SU; Doukky R; Metra M; Anker SD; Filippatos GS; Fonarow GC; Butler J
ESC Heart Fail; 2021 Feb; 8(1):16-25. PubMed ID: 33191637
[TBL] [Abstract][Full Text] [Related]
25. Reasons for and associated characteristics with early study termination: Analysis of ClinicalTrials.gov data on pregnancy topics.
Shieh C; Ofner S; Draucker CB
Nurs Outlook; 2022; 70(2):271-279. PubMed ID: 35090741
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Terminated Hand and Wrist-Related Clinical Trials.
Delma S; Foster BK; Baylor JL; Ozdag Y; Manzar S; Langford K; Klena JC; Grandizio LC
J Hand Surg Glob Online; 2023 Sep; 5(5):673-676. PubMed ID: 37790828
[TBL] [Abstract][Full Text] [Related]
27. Discontinuation and nonpublication of clinical trials in orthopaedic oncology.
Singh G; Wague A; Arora A; Rao V; Ward D; Barry J
J Orthop Surg Res; 2024 Feb; 19(1):121. PubMed ID: 38317223
[TBL] [Abstract][Full Text] [Related]
28. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M
J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277
[TBL] [Abstract][Full Text] [Related]
29. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
Paul K; Sathianathen N; Dahm P; Le C; Konety BR
J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
[TBL] [Abstract][Full Text] [Related]
30. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
31. Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data.
Stensland K; Kaffenberger S; Canes D; Galsky M; Skolarus T; Moinzadeh A
JCO Clin Cancer Inform; 2020 Jul; 4():614-622. PubMed ID: 32667822
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of Ophthalmology Trials Registered in ClinicalTrials.gov, 2007-2018.
Turner B; Rajeshuni N; Tran EM; Ludwig CA; Tauqeer Z; Weeks B; Kinde B; Pershing S
Am J Ophthalmol; 2020 Mar; 211():132-141. PubMed ID: 31730839
[TBL] [Abstract][Full Text] [Related]
33. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015.
Baldi I; Lanera C; Berchialla P; Gregori D
BMJ Open; 2017 Jun; 7(6):e013482. PubMed ID: 28619765
[TBL] [Abstract][Full Text] [Related]
34. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019.
Gresham G; Meinert JL; Gresham AG; Meinert CL
JAMA Netw Open; 2020 Aug; 3(8):e2014682. PubMed ID: 32845329
[TBL] [Abstract][Full Text] [Related]
35. Sponsorship of oncology clinical trials in the United States according to age of eligibility.
Neel DV; Shulman DS; Ma C; Bourgeois F; DuBois SG
Cancer Med; 2020 Jul; 9(13):4495-4500. PubMed ID: 32351000
[TBL] [Abstract][Full Text] [Related]
36. A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies.
Cheng SK; Dietrich MS; Dilts DM
Clin Cancer Res; 2010 Nov; 16(22):5557-63. PubMed ID: 21062929
[TBL] [Abstract][Full Text] [Related]
37. Rates of Discontinuation and Nonpublication of Head and Neck Cancer Randomized Clinical Trials.
Johnson AL; Fladie I; Anderson JM; Lewis DM; Mons BR; Vassar M
JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):176-182. PubMed ID: 31876933
[TBL] [Abstract][Full Text] [Related]
38. Delayed discovery: the COVID-19 pandemic's influence on osteoarthritis clinical trials.
Sajjadi NB; Anderson JM; Hughes GK; Abraham CE; Malik J; Hartwell M; Vassar M
J Osteopath Med; 2024 Jan; 124(1):5-11. PubMed ID: 37580988
[TBL] [Abstract][Full Text] [Related]
39. Outcome reporting among drug trials registered in ClinicalTrials.gov.
Bourgeois FT; Murthy S; Mandl KD
Ann Intern Med; 2010 Aug; 153(3):158-66. PubMed ID: 20679560
[TBL] [Abstract][Full Text] [Related]
40. Early Discontinuation, Results Reporting, and Publication of Pediatric Clinical Trials.
Brewster R; Wong M; Magnani CJ; Gunningham H; Hoffer M; Showalter S; Tran K; Steinberg JR; Turner BE; Goodman SN; Schroeder AR
Pediatrics; 2022 Apr; 149(4):. PubMed ID: 35314864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
